Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Replimune Group, Inc.

NASDAQ: REPL · Life Sciences · 5 alerts · CIK 1737953

Share price
$21.41Close, Nov 16
Market cap
$2.03B
Shares outstanding
94.8MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Replimune Group, Inc. filings on SEC EDGAR ↗

4:30 PM ET Form 4
Insider Selling

Replimune Group Insider Joseph P. Slattery Sells $113K of Stock

Joseph P. Slattery sold 5,200 shares of Replimune Group, Inc. at $21.80 a share, worth $113K in total on Nov 9, 2026. Shares held after the trade: 1,467 (-78.0%).

Value
$113K
Shares
5,200
Price
$21.80
Holding change
-78.0%
Trade date
Nov 9, 2026
8:44 PM ET Form 4
Insider Selling

Replimune Group Insider Kapil Dhingra Sells $408K of Stock

Kapil Dhingra sold 21,500 shares of Replimune Group, Inc. at $19.00 a share, worth $408K in total on Nov 2, 2026. Shares held after the trade: 21,669 (-49.8%).

Value
$408K
Shares
21,500
Price
$19.00
Holding change
-49.8%
Trade date
Nov 2, 2026
7:26 AM ET 10-Q
Financial Results

Replimune Group Q2 2026 Results: Net Loss of $57.1M, Loss Narrows

Replimune Group, Inc. reported a net loss of $126.9 million for the six months ended September 30, 2026, an improvement from the $169.8 million loss in the prior year period. The company significantly strengthened its cash position to $307.8 million through the issuance of common stock and pre-funded warrants, while transitioning to a commercial-stage biotechnology company.

Key figure
Net loss $57.1M
7:06 AM ET 8-K
Financial Results

Replimune Group Financial Results

Replimune Group reported financial results for its fiscal second quarter 2027 and provided a commercial update on the U.S. launch of TUDRIQEV for advanced melanoma. The product became commercially available on October 6, 2026, with more than 15 institutions already prescribing the therapy and over 70% of priority accounts engaged for adoption.

Term
fiscal second quarter ended September 30, 2026

“TUDRIQEV is now available to patients in urgent need. The response from physicians has been enthusiastic and both oncologists and interventional radiologists are eager to bring TUDRIQEV into their practices. They value the broad label that lets them treat patients immediately after progression on a PD-1 based therapy. We are focused on reaching as many of these patients as possible.”

Sushil Patel, Ph.D., CEO of Replimune
4:06 PM ET 8-K
Shareholder Meeting

Replimune Group Shareholder Meeting

Replimune Group held its 2026 Annual Meeting of Stockholders where shareholders approved an amendment to the Certificate of Incorporation to double the number of authorized shares of common stock from 150 million to 300 million. Stockholders also ratified the selection of PricewaterhouseCoopers LLP as the independent auditor and approved executive compensation on an advisory basis.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.